The trial will include patients suffering from moderately-to-severely active Crohn’s disease despite treatment with a tumor necrosis factor antagonist drug, and it will be held at five different research centers in Europe. The company’s neuromodulation device is designed to stimulate the body’s vagus nerve and thereby create an anti-inflammatory effect.
SetPoint Medical is a biotech company developing therapies for the treatment of a variety of inflammation-mediated autoimmune diseases, according to the report.
More articles on gastroenterology:
Dr. Thomas Savides named 1st UC San Diego Chief Experience Officer
8 gastroenterologist moves & honors
3 Mount Sinai GI physicians win all 2014 Crohn’s & Colitis Foundation of America awards
